Clinical Trials

CRETI-NH: Phase I Study Of CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin’s Lymphoma And Chronic Lymphocytic Leukemia (H-19384) (H-19384)

H-19384: Phase I Study Of CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin’s Lymphoma And Chronic Lymphocytic Leukemia (CRETI-NH): This study uses a chimeric receptor made from T cells that kill tumor cells and an antibody called anti-CD19 that sticks to lymphoma cells to try to treat non-Hodgkin’s lymphoma and CLL.

For more information:http://www.clinicaltrials.gov/ct2/show/NCT00608270